Importance of Bladder Radioactivity for Radiation Safety in Nuclear Medicine

Nükleer Tipta Rasyasyon Güvenliği İçin Mesane Radyoaktivitesinin Önemi

Salih Sinan Gültekin, Turan Şahmaran
Department of Nuclear Medicine, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey

Abstract
Objective: Most of the radiopharmaceuticals used in nuclear medicine are excreted via the urinary system. This study evaluated the importance of a reduction in bladder radioactivity for radiation safety.
Methods: The study group of 135 patients underwent several organ scintigraphies [40/135; thyroid scintigraphy (TS), 30/135; whole body bone scintigraphy (WBS), 35/135; myocardial perfusion scintigraphy (MPS) and 30/135; renal scintigraphy (RS)] by a technologist within 1 month. In full and empty conditions, static bladder images and external dose rate measurements at 0.25, 0.50, 1, 1.5 and 2 m distances were obtained and decline ratios were calculated from these two data sets.
Results: External radiation dose rates were highest in patients undergoing MPS. External dose rates at 0.25 m distance for TS, TKS, MPS and BS were measured to be 56, 106, 191 and 72 µSv h⁻¹ for full bladder and 29, 55, 103 and 37 µSv h⁻¹ for empty bladder, respectively. For TS, WBS, MPS and RS, respectively, average decline ratios were calculated to be 52%, 55%, 53% and 54% in the scintigraphic assessment and 49%, 51%, 49%, 50% and 50% in the assessment with Geiger counter.
Conclusion: Decline in bladder radioactivity is important in terms of radiation safety. Patients should be encouraged for micturition after each scintigraphic test. Spending time together with radioactive patients at distances less than 1 m should be kept to a minimum where possible.

Key words: Radiation protection, radionuclide imaging, ionizing radiation, radiation effects, radiation monitoring

Özet
Amaç: Nükleer tipta kullanılan çoğu radyofarmasötik üriner sistem yoluya atlır. Bu çalışma rasyasyon güvenliği için mesane radyoaktivitesindeki azalmanın öneminin değerlendirildiği teşkil eder.
Yöntemler: Çalışma grubundaki 135 hasta 1 ay içinde çeşitli organ sintigrafileri [40/135; tiroit sintigrafisi (TS), 30/135; tüm vücut kemik sintigrafisi (TKS), 35/135; miyokart perfüzyon sintigrafisi (MPS) ve 30/135; böbrek sintigrafisi (BS)] yapılan hastalarda, dolu ve boş durumlarla, statik mesane görüntüleri ve 0.25, 0.50, 1, 1.5 ve 2 m mesafelerde dış doz hızlari ölçüldü ve bu iki veri setinden azalma oranları hesaplandı.
Bulgular: Dış radyasyon doz hızları MPS yapılan hastalarda en yüksekti. TS, TKS, MPS ve BS için 0.25 m mesafede dış doz hızları sırasıyla 56, 106, 191 ve 72 µSv h⁻¹ ve boş mesane için 29, 55, 103 ve 37 µSv h⁻¹ olarak ölçüldü. Sırasıyla TS, TKS, MPS ve BS için ortalamaları 52, 55, 53 ve 54 olarak bulundu.
Sonuç: Mesane radyoaktivitesindeki düşüş rasyasyon güvenliği açısından önemi vardır. Hastaların her sintigrafik test sonrasında işeme için teşvik edilmelidir. Mümkün olduğu takdirde 1 m'ın altında mesafelerde radyoaktif hastalar ile birlikte geçilen zaman minimuma tutulmalıdır.
Anahtar kelimeler: Rasyasyondan korunma, radyonüklid görüntüleme, iyonizan radyasyon, radyasyon etkileri, radyasyon monitörizasyonu

Address for Correspondence: Salih Sinan Gültekin MD, Department of Nuclear Medicine, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey Phone: +90 533 761 49 91 E-mail: gultekinsinan@gmail.com Received: 25.03.2013 Accepted: 26.07.2013

Molecular Imaging and Radionuclide Therapy, published by Galenos Publishing.
Introduction

Nuclear medicine staff and others who have close contact with radioactive patients are exposed to external radiation at various degrees. Although numerous radiopharmaceuticals in nuclear medicine have been used for diagnostic imaging studies, 99m-technetium (99mTc)-labeled agents are the most commonly used in routine nuclear medicine. In order to obtain target organ specific imaging, radiopharmaceuticals are generated by the combination of a radionuclide with a bioactive agent such as methylene diphosphonate (MDP), methoxy isobutyl isonitrile (MIBI), or diethyleneetriamine pentaacetic acid (DTPA). The urinary system is the main excretion route for most of the 99mTc-labeled radiopharmaceuticals used in nuclear medicine (1,2).

Radiation dose or dose rates per application and in total to staff within a time period such as daily, monthly or annually can be determined by two different methods (3,4,5,6,7,8). At first, it is calculated by measurements obtained at a fixed distance from the patient and some authors also take into consideration the time spent with the patient at a constant distance to calculate the amount of expected radiation exposure to technicians (4,5). In the other method the calculation is based on the direct reading of data obtained from the electronic pocket dosimeter of radiation workers (6,7,8).

In this study, conducted in a center performing routine nuclear medicine tests, an evaluation was made on the potential contribution of the decrease in bladder radioactivity after voiding to radiation safety.

Materials and Methods

The study group consisted of 135 patients (75 males, 60 females, age range: 21-85 years, mean age: 51±14 years). Scintigraphic studies were performed on all 135 patients within a 1-month period by the same technologist. This study was approved by the Local Ethics Committee of Dışkapı Yıldırım Beyazıt Training and Research Hospital and informed consent was obtained from the patients within a 1-month period by the same technologist. For WBS, anterior and posterior whole-body images were performed with one-day protocol. After i.v injection of 99mTc-MIBI with a 296 MBq (8 mCi) dose for the rest study and a 888 MBq (24 mCi) dose for the stress study, images were taken at 60 minutes and 30 minutes respectively after the injection. Following routine imaging, anterior static images of the bladder before and after voiding were taken. For RS, a 370 MBq (10 mCi) dose of 99mTc-DTPA was injected intravenously under the camera and dynamic imaging was performed for 40 minutes; at the 20th minute 1 mg/kg furosemide was administered intravenously. At the end of the routine imaging, anterior static images of the bladder were obtained for the full and empty bladder. On the anterior static images, a standard rectangular region of interest (ROI) of 2x2 cm was drawn on the bladder region for before (ROIl) and after (ROIa) voiding.

External radiation dose rate (EDR), simultaneous with the scintigraphic imaging, was measured at 0.25, 0.5, 1, 1.5 and 2 m distances from the skin at the level of the bladder before (EDRb) and after (EDRa) voiding using a Geiger counter (Ludlum 14C model, Pancake GM external detector, Ludlum Ins., USA). Calibration of this device was done in the Turkish Atomic Energy Agency, Nuclear Research and Training Center, Second Grade Standard Dosimetry Laboratory.

Decline ratio in radioactivity for scintigraphic and Geiger studies was calculated for all patients. This ratio shows the % difference between the measurements obtained with the full and empty bladder. The calculations were made using following formulas: \[ \frac{100 - \text{ROIa} \times \text{ROIb} \times 100}{\text{EDRa} / \text{EDRb} \times 100} \] for scintigraphic measurements and \[ \frac{100 - \text{ROIa} \times \text{ROIb} \times 100}{\text{EDRa} / \text{EDRb} \times 100} \] for Geiger measurements.

Results

Figure 1 presents the mean values of the EDR measurements obtained at 0.25, 0.5, 1, 1.5 and 2 m distances in patients with a full and empty bladder for various scintigraphic examinations, including TS, WBS, MPS and RS. EDR values in each scintigraphic test tend to decrease in direct proportion with the increasing distance and bladder emptying. EDRs were the highest at 0.25 m distance in patients with a full bladder undergoing MPS (191 \( \mu \text{Sv h}^{-1} \)) compared to the others (106 \( \mu \text{Sv h}^{-1} \) for WBS, 72 \( \mu \text{Sv h}^{-1} \) for RS and 56 \( \mu \text{Sv h}^{-1} \) for TS). EDR values were significantly higher at distances under 1 m when compared with the distances greater than 1 m. For example, for WBS in patients with a full bladder, EDR values were measured as 106 \( \mu \text{Sv h}^{-1} \) at 0.25 m and 68 \( \mu \text{Sv h}^{-1} \) at 0.5 m while the values were 27 \( \mu \text{Sv h}^{-1} \) at 1.5 m and 14 \( \mu \text{Sv h}^{-1} \) at 2 m.

Table 1 shows the average decline ratios in radioactivity between full and empty bladder for 0.25, 0.5, 1, 1.5 and 2 m distances. Average decline ratios range between 46% and 59% without any obvious effect of distance and scintigraphy type. In addition, Figure 2 demonstrates the total average decline ratios according to the scintigraphic...
tests for Geiger counter measurements and scintigraphic measurements. Although total decline ratios for the values obtained with the scintigraphic method are slightly higher than the values from the Geiger counter, the results obtained by both methods still support each other. As a result, these findings have shown that a reduction of about 50% in external radiation exposure via disposal of bladder radiation could be achieved.

Discussion

Some authors have stated that external radiation exposure from radioactive patients is a matter of priority for radiation safety of nuclear medicine staff and the public (7,9). Technologists are frequently exposed to external radiation while performing procedures such as preparing and administering radiopharmaceuticals, positioning the patients under the gamma camera, data acquisition, removing the patients from the bed and accompanying the radioactive patient (3). The received external radiation dose can be reduced by various measures (3,7,10). Several authors have studied external radiation doses and protection methods (3,4,5,6,7,8,10,11).

Bayram et al. (3) found that $^{99m}$Tc-MIBI MPS gave higher doses to technologists when compared with other scintigraphies using $^{99m}$Tc-labeled agents. Chiesa et al. (4) reported that the measured dose range for most typical scintigraphic tests was within 0.2-0.4 $\mu$Sv except for two; equilibrium angiocardioscintigraphy (1.0+-0.5 $\mu$Sv) and $^{99m}$Tc-MIBI single-photon emission computed tomography (1.7+-1.0 $\mu$Sv). Clarke et al. (6) reported that an average radiation dose experienced by a technologist was 1.5 $\mu$Sv per scintigraphic study for routine procedures other than cardiac studies, and was a total of 5.5 $\mu$Sv (rest;1.0 $\mu$Sv, exercise;2.5 $\mu$Sv and pharmacological; 2.0 $\mu$Sv) for cardiac

| Distances | TS (n:40) | WBS (n:30) | MPS (n:35) | RS (n:30) |
|-----------|-----------|------------|------------|-----------|
| 0.25 m    | 48%       | 48%        | 46%        | 48%       |
| 0.50 m    | 51%       | 51%        | 48%        | 46%       |
| 1 m       | 47%       | 48%        | 50%        | 49%       |
| 1.5 m     | 49%       | 54%        | 52%        | 50%       |
| 2 m       | 50%       | 52%        | 49%        | 59%       |

MPS; Myocardial perfusion scintigraphy, RS; Renal scintigraphy, TS; Thyroid scintigraphy, WBS; Whole-body bone scintigraphy

Figure 1. Comparison of average radiation dose rate measurements obtained for full and empty bladder status at 0.25, 0.50, 1.5 and 2 m from patients undergoing thyroid scintigraphy, whole-body bone scintigraphy, myocardial perfusion scintigraphy and renal scintigraphy.

Figure 2. The percentage distribution of the total average decline ratios in radioactivity according to the type of scintigraphic examinations for the measurements obtained from Geiger counter and scintigraphic method.
procedures with $^{99m}$Tc-MIBI or tetrofosmin. Culver et al. (10) calculated the average monthly dose to nuclear medicine technologists by whole-body film badge readings and they found that it was significantly higher for $^{99m}$Tc-MIBI than $^{201}$TI (450 μSv vs. 100 μSv, $p < 0.001$). In addition, 360 μSv was reported for noninvasive cardiology staff. The findings of the current study concur that MPS using $^{99m}$Tc-MIBI causes higher EDR than other traditional scintigraphic studies with $^{99m}$Tc-labeled agents. Greaves and Tindale (11) measured the maximum dose rate at a distance of 0.1 m for MPS using $^{99m}$Tc-MIBI. This value was found to be 391.74 μSv h⁻¹ for the one-day protocol and 121.84 μSv h⁻¹ for the two-day protocol. In the current study, in the full bladder state, a dose rate of 498 μSv h⁻¹ was measured at 0.25 m for $^{99m}$Tc-MIBI study in the one-day protocol. Gomes-Palacios et al. (5) stated that the maximum dose from MPS with a double injection of $^{99m}$Tc-MIBI was 499 μSv and there was no probability of staff receiving a higher dose than the permissible limits. Lundberg et al. (8) found that doses to the technologist were 5.4 μSv/d and 1.4 mSv/y for scanning and these levels were much lower than the regulatory limits. These findings were consistent with the findings of this study.

Smart et al. (7) found that the usage of a 0.5 mm lead apron for gated stress MPS with $^{99m}$Tc-MIBI resulted in a significant decrease (0.58±0.56 μSv vs. 1.10±0.45 μSv, 47%) in radiation dose exposure for the technologist. In a study by Bayram et al. (3) the ranges of deep-dose equivalent for technologists from routine scintigraphic examinations (T5, WBS, MPS and RS) were 0.13±0.05 to 0.43±0.17 μSv with a lead shield and 0.21±0.07 to 1.01±0.46 μSv without a lead shield, with a decrease in the range of 38% - 57%. In this study, it was demonstrated that a significant decline in radiation exposure, equivalent to the use of a protective lead apron, could be obtained by effective micturition of radioactive patients. This decline was determined to be in a range between 52% and 55% according to the scintigraphic measurements and between 49% and %51 according to the Geiger counter measurements. We found that median values of the radiation dose rates measured at various distances were the values measured at 1 m distance, and the mean values were between the values measured at 0.5 and 1 m distances. To reduce the radiation exposure of radiation workers at distances less than 1 m, we suggest that staff should carry out their work related to radioactive patients carefully and as quickly as possible while remaining within professional limits.

**Conclusion**

Reduction in bladder radioactivity after voiding is a practice that provides a significant decrease in radiation exposure for the staff and any others in the vicinity of the patient. Patients should be encouraged to go to the toilet before and after scintigraphic tests to achieve a higher level of radiation safety. Spending time together with radioactive patients at distances less than 1 m should be kept to a minimum whenever possible.

**References**

1. Demir M. Nükleer Tıp Fiziği ve Klinik Uygulamaları. 3th ed. İstanbul 2011;43-85.
2. Değer M, Demir M, İnce M, Kirac S, Koseoglu K, Turan E, Uysal B. Kalite Kontrol, Enstrumantasyon ve Radyasyon Güvenliği Yönergesi. Turk J Nucl Med 2004;13:118-139.
3. Bayram T, Yilmaz AH, Demir M, Sonmez B. Radiation Dose to Technologists per Nuclear Medicine Examination and Estimation of Annual Dose. J Nucl Med Technol 2011;39:55-59.
4. Chiesa C, De Sanctis V, Crippa E, Schiavini M, Fragiola CE, Bogni A, Pascali C, Decise D, Marchesini R, Bombardieri E. Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-$^{99m}$, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1997;24:1380-1389.
5. Gomez-Palacios M, Terron JA, Dominguez P, Vera DR, Osuna RF. Radiation doses in the surroundings of patients undergoing nuclear medicine diagnostic studies. Health Phys 2005;89:27-34.
6. Clarke EA, Notghi A, Harding LK. Are MIBI/tetrofosmin heart studies a potential radiation hazard to technologists? Nucl Med Commun 1997;18:574-577.
7. Smart R. Task-specific monitoring of nuclear medicine technologists’ radiation exposure. Radiat Prot Dosimetry 2004;109:201-209.
8. Lundberg TM, Gray PJ, Bartlett ML. Measuring and minimizing the radiation dose to nuclear medicine technologists. J Nucl Med Technol 2002;30:25-30.
9. Thomson WH, Harding LK. Radiation protection issues associated with nuclear medicine out-patients. Nucl Med Commun 1995;16:879-892.
10. Culver CM, Dworkin HJ. Comparison of personnel radiation dosimetry from myocardial perfusion scintigraphy: technetium-$^{99m}$, sestamibi versus thallium-201. J Nucl Med 1993;34:1210-1213.
11. Greaves CD, and Tindale WB. Dose rate measurements from radiopharmaceuticals: Implications for nuclear medicine staff and for children with radioactive parents. Nuc Med Commun 1999;20:179-187.
12. Robinson IF. Optimisation and common sense. J Radiol Prot 2002;22:57-61.